SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-21-040821
Filing Date
2021-08-04
Accepted
2021-08-04 16:13:42
Documents
63
Period of Report
2021-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q fate-10q_20210630.htm   iXBRL 10-Q 2744441
2 EX-10.1 fate-ex101_195.htm EX-10.1 18750
3 EX-31.1 fate-ex311_6.htm EX-31.1 9826
4 EX-31.2 fate-ex312_8.htm EX-31.2 9922
5 EX-32.1 fate-ex321_7.htm EX-32.1 6847
  Complete submission text file 0001564590-21-040821.txt   11295813

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA fate-20210630.xsd EX-101.SCH 63291
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE fate-20210630_cal.xml EX-101.CAL 48492
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE fate-20210630_def.xml EX-101.DEF 248170
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE fate-20210630_lab.xml EX-101.LAB 484032
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fate-20210630_pre.xml EX-101.PRE 387066
11 EXTRACTED XBRL INSTANCE DOCUMENT fate-10q_20210630_htm.xml XML 2742121
Mailing Address 3535 GENERAL ATOMICS COURT SUITE 200 SAN DIEGO CA 92121
Business Address 3535 GENERAL ATOMICS COURT SUITE 200 SAN DIEGO CA 92121 858.875.1803
FATE THERAPEUTICS INC (Filer) CIK: 0001434316 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36076 | Film No.: 211144173
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences